Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2006

01-07-2006 | Review

Antipsychotic drugs and diabetes—an application of the Austin Bradford Hill criteria

Authors: R. I. G. Holt, R. C. Peveler

Published in: Diabetologia | Issue 7/2006

Login to get access

Abstract

There is concern that antipsychotic drugs cause diabetes. Although there has been an explosion in the quantity of literature about this subject, it remains confusing and inconsistent. To assess whether the association between antipsychotic drugs and diabetes is causative, we applied the Austin Bradford Hill criteria to the available evidence. In support of a causative relationship, there is temporality for some cases of diabetes, and there is a biologically plausible explanation. The causative link between antipsychotic drugs and diabetes is coherent with our understanding of diabetes and there are other analogies. However the strength of association is weak, there is lack of consistency or specificity, and there is little evidence to support a biological gradient. We should therefore conclude that the evidence surrounding a causative link between antipsychotic drugs and diabetes is inconclusive. Moreover, the risk is probably low and the attributable risk of developing diabetes is greater for traditional risk factors such as family history, ethnicity, obesity and ageing than it is for receiving an antipsychotic drug. Consequently, the majority of patients receiving second-generation antipsychotics will not develop diabetes as a result of their medication.
Appendix
Available only for authorised users
Literature
1.
Holt RIG, Bushe C, Citrome L (2005) Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psychopharmacol 19:56–65PubMedCrossRef
2.
3.
Pus PE (2004) Vliv farmaceutickeho prumyslu na vzdelavani lekaru. Psychiatrie (Czech) 8:332
4.
Stahl SM (2005) Detecting and dealing with bias in psychopharmacology. PsychEd Up 1:6–7
5.
Brown S, Birtwistle J, Roe L, Thompson C (1999) The unhealthy lifestyle of people with schizophrenia. Psychological Med 29:697–701CrossRef
6.
Cheta D, Dumitrescu C, Georgescu M et al (1990) A study on the types of diabetes mellitus in first degree relatives of diabetic patients. Diabetes Metab 16:11–15
7.
Mukherjee S, Schnur DB, Reddy R (1989) Family history of type 2 diabetes in schizophrenic patients. Lancet 1:495PubMedCrossRef
8.
McCreadie R, Macdonald E, Blacklock C et al (1998) Dietary intake of schizophrenic patients in Nithsdale, Scotland: case–control study. BMJ 317:78–785
9.
Taylor D, Young C, Esop R, Paton C, Walwyn R (2004) Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 185:152–156PubMedCrossRef
10.
11.
Subramaniam M, Chong SA, Pek E (2003) Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 48:345–347PubMed
12.
Hill AB (1965) The environment and disease; association or causation. Proc Royal Soc Med 58:295–330
13.
Shakir SA, Layton D (2002) Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Saf 25:467–471PubMedCrossRef
14.
Haddad PM (2004) Antipsychotics and diabetes: review of non-prospective data. Br J Psychiatry 47(Suppl):S80–S86CrossRef
15.
Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA (2002) Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 63:920–930PubMed
16.
Gianfrancesco F, White R, Wang RH, Nasrallah HA (2003) Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 23:328–335PubMedCrossRef
17.
Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L (2003) A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 56:164–170PubMedCrossRef
18.
Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D (2003) Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 25:1150–1171PubMedCrossRef
19.
Etminan M, Streiner DL, Rochon PA (2003) Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy 23:1411–1415PubMedCrossRef
20.
Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J (2002) Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 22:236–243PubMedCrossRef
21.
Koro CE, Fedder DO, L’Italien GJ et al (2002) Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case–control study. BMJ 325:243PubMedCrossRef
22.
Kornegay CJ, Vasilakis-Scaramozza C, Jick H (2002) Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 63:758–762PubMed
23.
Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R (2002) Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159:561–566PubMedCrossRef
24.
Lund BC, Perry PJ, Brooks JM, Arndt S (2001) Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 58:1172–1176PubMedCrossRef
25.
Caro JJ, Ward A, Levinton C, Robinson K (2002) The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 63:1135–1139PubMed
26.
Fuller MA, Shermock KM, Secic M, Grogg AL (2003) Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 23:1037–1043PubMedCrossRef
27.
Smith RC, Lindenmayer JP, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A (2005) Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol:1–12
28.
Taylor D, Young C, Mohamed R, Paton C, Walwyn R (2005) Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 19:182–186PubMedCrossRef
29.
Citrome LL, Jaffe A, Levine J, Allingham B, Robinson J (2004) Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 55:1006–1013PubMedCrossRef
30.
Barner JC, Worchel J, Yang M (2004) Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among Central Texas veterans. Pharmacotherapy 24:1529–1538PubMedCrossRef
31.
Leslie DL, Rosenheck RA (2004) Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 161:1709–1711PubMedCrossRef
32.
Ollendorf DA, Joyce AT, Rucker M (2004) Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. Med Gen Med 6:5
33.
Miller EA, Leslie DL, Rosenheck RA (2005) Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis 193:387–395PubMedCrossRef
34.
Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W (2005) Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case–control study of California Medicaid claims. Pharmacoepidemiol Drug Saf 14:417–425PubMedCrossRef
35.
Mackin P, Watkinson HM, Young AH (2005) Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 48:215–221PubMedCrossRef
36.
Spoelstra JA, Stolk RP, Cohen D et al (2004) Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. J Clin Psychiatry 65:674–678PubMed
37.
Biswas PN, Wilton LV, Pearcel GL, Freemantle S, Shakir SA (2001) The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol 15:265–271CrossRef
38.
Citrome LL (2004) The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs Today 40:445–464PubMedCrossRef
39.
Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO (2004) Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 161:1837–1847PubMedCrossRef
40.
Kane JM (2003) Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. J Clin Psychiatry 64(Suppl 19):19–25PubMed
41.
Lieberman JA, Tollefson G, Tohen M et al (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160:1396–1404PubMedCrossRef
42.
McQuade RD, Stock E, Marcus R et al (2004) A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65(Suppl 18):47–56PubMed
43.
Bushe C, Holt R (2004) Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry (Suppl 47):S67–S71
44.
Lieberman JA, Phillips M, Gu H et al (2003) Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacol 28:995–1003
45.
Lindenmayer JP, Czobor P, Volavka J et al (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160:290–296PubMedCrossRef
46.
Torbeyns A, Marder S, Carson W et al (2004) Glycaemic control and plasma lipids in long term treatment with aripiprazole. Schizophrenia Res 67(Suppl):S192
47.
Beasley CM Jr, Sutton VK, Hamilton SH et al (2003) A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 23:582–594PubMedCrossRef
48.
Marder SR, McQuade RD, Stock E et al (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123–136PubMedCrossRef
49.
Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223PubMedCrossRef
50.
Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP (2005) Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. Int J Neuropsychopharmacol:1–8
51.
Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP (2004) A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 65:696–701PubMed
52.
McEvoy JP, Meyer JM, Goff DC et al (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19–32PubMedCrossRef
53.
Lorenz WF (1922) Sugar intolerance in dementia praecox and other mental disorders. Arch Neurol Psychiatry 8:184–196
54.
Appel KE, Farr CB (1929) Blood sugar reaction to insulin in psychoses. Arch Neurol Psychiatry 21:145–148
55.
Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284–289PubMedCrossRef
56.
Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R (2002) Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 26:137–141PubMedCrossRef
57.
Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 184:58–62PubMedCrossRef
58.
Arranz B, Rosel P, Ramirez N et al (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65:1335–1342PubMed
59.
Balter J, Mofsen R, Pinninti N (2004) Quetiapine in the successful treatment of psychosis and comorbid brittle diabetes mellitus: a case report. Int J Psychiatry Med 34:259–266PubMedCrossRef
60.
Citrome L, Jaffe A, Levine J (2005) Dosing of second-generation antipsychotic medication in a state hospital system. J Clin Psychopharmacol 25:388–391PubMedCrossRef
61.
Perry PJ, Argo TR, Carnahan RM et al (2005) The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol 25:250–254PubMedCrossRef
62.
Haddad P (2005) Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 19:16–27PubMedCrossRef
63.
Allison DB, Mentore JL, Heo M et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–1696PubMed
64.
Lambert M, Haro JM, Novick D et al (2005) Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand 111:232–243PubMedCrossRef
65.
Potkin SG, Saha AR, Kujawa MJ et al (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681–690PubMedCrossRef
66.
Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S (2005) Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 25:255–258PubMedCrossRef
67.
Jin H, Meyer JM, Jeste DV (2002) Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 14:59–64PubMed
68.
Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M (2004) Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 65:471–477PubMedCrossRef
69.
Sowell M, Mukhopadhyay N, Cavazzoni P et al (2003) Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 88:5875–5880PubMedCrossRef
70.
Sowell MO, Mukhopadhyay N, Cavazzoni P et al (2002) Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 87:2918–2923PubMedCrossRef
71.
Engl J, Laimer M, Niederwanger A et al (2005) Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry 10:1089–1096PubMedCrossRef
72.
Ader M, Kim SP, Catalano KJ et al (2005) Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54:862–871PubMedCrossRef
73.
Baptista T, Alvarez L, Lacruz A, de Mendoza S, Hernandez L (1999) Glucose tolerance and serum insulin levels in an animal model of obesity induced by sub-acute or chronic administration of antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 23:277–287PubMedCrossRef
74.
Bushe C, Paton C (2005) The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link? J Psychopharmacol 19:76–83PubMedCrossRef
75.
Melkersson K, Jansson E (2005) The atypical antipsychotics quetiapine, risperidone and ziprasidone do not increase insulin release in vitro. Neuro Endocrinol Lett 26:205–208PubMed
76.
Avram AM, Patel V, Taylor HC, Kirwan JP, Kalhan S (2001) Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacotherapy 35:1381–1387CrossRef
77.
Jick H, Garcia Rodriguez LA, Perez-Gutthann S (1998) Principles of epidemiological research on adverse and beneficial drug effects. Lancet 352:1767–1770PubMedCrossRef
Metadata
Title
Antipsychotic drugs and diabetes—an application of the Austin Bradford Hill criteria
Authors
R. I. G. Holt
R. C. Peveler
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0279-3

Other articles of this Issue 7/2006

Diabetologia 7/2006 Go to the issue

Letter-comment

Comment to: Martin S, Schneider B, Heinemann L et al (2006) Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 49:271–278

Article

What determines the cost-effectiveness of diabetes screening?

Article

Age at introduction of new foods and advanced beta cell autoimmunity in young children with HLA-conferred susceptibility to type 1 diabetes

Letter

Comment to: Hoi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B (2005) The Somogyi phenomenon revisited using continuous glucose monitoring in daily life. Diabetologia 48:2437–2438

Article

Common variants in MODY genes increase the risk of gestational diabetes mellitus

Article

High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits